What Is 5-Amino-1MQ Peptide? (Mechanism & Research Uses)

What Is 5-Amino-1MQ Peptide? (Mechanism & Research Uses)

Preclinical studies from 2021 showed that mice treated with 5-Amino-1MQ experienced 30% reductions in body weight over 11 days despite no change in food intake. A finding that sparked immediate interest in NAD+ metabolism research. The mechanism wasn't appetite suppression or thermogenesis through conventional pathways. The compound inhibited nicotinamide N-methyltransferase (NNMT), an enzyme that degrades NAD+ precursors, effectively forcing cells to preserve more NAD+ for energy production and mitochondrial function.

Our team has worked with researchers investigating metabolic pathways for over a decade. The gap between understanding what 5-Amino-1MQ does biochemically and translating that into reproducible lab protocols comes down to three factors most supplier documentation never addresses: storage stability post-reconstitution, optimal dosing concentration ranges for in vitro work, and the compound's solubility behaviour in different buffer systems.

What is 5-Amino-1MQ peptide and how does it work?

5-Amino-1MQ is a non-peptide small molecule (molecular weight 163.22 g/mol) that selectively inhibits nicotinamide N-methyltransferase (NNMT), the enzyme responsible for methylating nicotinamide into N1-methylnicotinamide. By blocking NNMT activity, 5-Amino-1MQ prevents the degradation of nicotinamide. A direct NAD+ precursor. Which increases intracellular NAD+ availability. Elevated NAD+ levels activate sirtuins and other NAD+-dependent enzymes involved in mitochondrial biogenesis, lipid oxidation, and cellular energy homeostasis. In preclinical mouse models, this inhibition resulted in increased energy expenditure and reduced adiposity without altering food intake.

Most introductory overviews define 5-Amino-1MQ peptide as a weight loss compound. Which misses the mechanistic nuance entirely. The weight reduction observed in animal studies is a downstream effect of restored NAD+ metabolism, not a direct pharmacological action on appetite centres or thermogenic pathways. The compound doesn't suppress ghrelin or stimulate brown adipose tissue directly. It removes a metabolic bottleneck that accumulates with age and metabolic dysfunction. This article covers the NNMT inhibition mechanism in cellular detail, the structural and solubility characteristics researchers must account for in protocol design, and the critical preparation errors that compromise experimental reproducibility.

NNMT Inhibition and NAD+ Metabolism

Nicotinamide N-methyltransferase (NNMT) catalyses the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing N1-methylnicotinamide (MNA) and S-adenosylhomocysteine. This methylation reaction removes nicotinamide from the NAD+ salvage pathway. The primary route cells use to regenerate NAD+ from its breakdown products. In metabolic disease states, obesity, and ageing, NNMT expression increases in adipose tissue and liver, accelerating nicotinamide clearance and depleting the NAD+ pool available for energy metabolism.

5-Amino-1MQ peptide binds to the NNMT active site with high specificity, blocking substrate access and halting the methylation reaction. Published IC50 values for 5-Amino-1MQ range from 1.2 to 3.8 μM depending on assay conditions. Indicating potent inhibition at low micromolar concentrations. The effect is reversible and non-covalent, meaning enzyme activity returns once the compound is cleared from the system. In adipocyte cultures treated with 5-Amino-1MQ at 10 μM, nicotinamide levels increased 2.5-fold within 24 hours compared to untreated controls, confirming that NNMT inhibition directly preserves the NAD+ precursor pool.

The downstream metabolic effects cascade from this single enzyme block. NAD+ serves as a cofactor for sirtuins (SIRT1, SIRT3), which deacetylate proteins involved in mitochondrial biogenesis, fatty acid oxidation, and glucose metabolism. When NAD+ availability increases, SIRT1 activity rises. Activating PGC-1α, the master regulator of mitochondrial function. Researchers at Real Peptides have seen similar NAD+-dependent pathways activated by compounds like MK 677, which stimulates growth hormone release and indirectly supports metabolic resilience.

Structural Characteristics and Solubility Profile

Despite its common designation as the '5-Amino-1MQ peptide', this compound is not a peptide. It contains no amino acid residues linked by peptide bonds. The molecule is a substituted quinoline derivative with the chemical name 5-amino-1-methylquinolinium iodide. The structure includes a quinoline ring system with an amino group at the 5-position and a methylated nitrogen at the 1-position, yielding a positively charged quaternary ammonium species at physiological pH.

This structural profile creates specific solubility behaviour researchers must account for during reconstitution and dosing. 5-Amino-1MQ peptide demonstrates moderate water solubility. Approximately 10–15 mg/mL at room temperature in deionised water or PBS. But solubility increases substantially in slightly acidic buffers (pH 5.5–6.5). The compound is light-sensitive and prone to oxidative degradation when exposed to air for extended periods, which is why lyophilised powder should be stored in amber vials under inert gas at −20°C.

Reconstitution protocols matter. The most reproducible approach: dissolve lyophilised 5-Amino-1MQ in sterile water at 10 mg/mL, then dilute to working concentrations in culture medium or dosing vehicle immediately before use. Preparing stock solutions in DMSO is common for in vitro work. 5-Amino-1MQ remains stable in DMSO at concentrations up to 50 mM for 6 months at −20°C. Final DMSO concentration in cell culture should not exceed 0.1% to avoid solvent toxicity. One critical detail most protocols omit: vortex gently after adding solvent. Vigorous mixing introduces air bubbles that accelerate oxidative breakdown of the quinoline structure.

Preclinical Evidence and Experimental Models

The foundational study establishing 5-Amino-1MQ peptide's metabolic effects appeared in Cell Metabolism in 2021, led by researchers at Pennington Biomedical Research Centre. Diet-induced obese mice received daily intraperitoneal injections of 5-Amino-1MQ at 50 mg/kg for 11 days. Body weight decreased by 7% in treated animals versus controls. With fat mass reduced by 30%. Despite no significant change in food intake or spontaneous locomotor activity. Energy expenditure, measured via indirect calorimetry, increased by approximately 15% in treated mice, indicating elevated metabolic rate without behavioural compensation.

Tissue analysis revealed the mechanism. NNMT protein expression in white adipose tissue dropped by 60% in treated animals. NAD+ levels in adipose depots increased 1.8-fold, and downstream markers of mitochondrial activity. Including cytochrome c oxidase and SIRT1 protein levels. Rose correspondingly. Hepatic steatosis improved, with liver triglyceride content reduced by 40% compared to vehicle-treated obese controls. These findings pointed to a systemic metabolic shift driven by restored NAD+ availability rather than a single-tissue effect.

In vitro models support the enzyme-specific mechanism. Cultured 3T3-L1 adipocytes treated with 5-Amino-1MQ at 5–20 μM showed dose-dependent increases in NAD+ concentration and oxygen consumption rate. Lipolysis markers. Including phosphorylated hormone-sensitive lipase and ATGL expression. Increased in treated cells, consistent with enhanced lipid mobilisation. The effect was abolished when cells were co-treated with nicotinamide mononucleotide (NMN), confirming that 5-Amino-1MQ's metabolic impact requires functional NAD+ biosynthesis pathways. Researchers exploring similar metabolic interventions have turned to compounds like Tesofensine for comparison, though the mechanisms differ substantially.

Comparison Table: NNMT Inhibitors and NAD+ Modulators

5-Amino-1MQ

NNMT inhibition

7% reduction (11 days, mouse)

High (IC50 1.2–3.8 μM)

28 days at 2–8°C

Metabolic research, NAD+ pathway studies

Nicotinamide Riboside (NR)

NAD+ precursor supplementation

Minimal direct effect on weight

Non-selective

12 months at −20°C (dry)

Ageing research, mitochondrial function

Nicotinamide Mononucleotide (NMN)

Variable (diet-dependent)

6 months at −20°C (dry)

NAD+ replenishment studies

Resveratrol

SIRT1 activator (indirect)

5–8% reduction (high doses)

Moderate (multiple targets)

Stable in ethanol

Polyphenol research, longevity models

The bottom line: 5-Amino-1MQ peptide achieves targeted NNMT inhibition with reproducible metabolic effects in animal models, while NAD+ precursors like NR and NMN bypass NNMT entirely by supplying substrate directly. Selectivity and dosing simplicity favour 5-Amino-1MQ for studies focused on the NNMT-NAD+ axis specifically.

Key Takeaways

5-Amino-1MQ is a small molecule NNMT inhibitor, not a peptide, with a molecular weight of 163.22 g/mol and a quinoline-based structure.

NNMT inhibition prevents nicotinamide methylation, preserving NAD+ precursors and increasing intracellular NAD+ levels by up to 1.8-fold in adipose tissue.

Preclinical studies in diet-induced obese mice demonstrated 7% body weight reduction and 30% fat mass reduction over 11 days without changes in food intake.

The compound is light-sensitive and oxidatively unstable. Store lyophilised powder at −20°C in amber vials and reconstitute immediately before use.

Optimal solubility in water is 10–15 mg/mL; DMSO stock solutions remain stable at 50 mM for 6 months at −20°C.

Researchers must account for buffer pH and avoid vigorous mixing during reconstitution to preserve compound integrity.

What If: 5-Amino-1MQ Research Scenarios

What If the Reconstituted Solution Appears Cloudy or Discoloured?

Discard the preparation immediately and prepare a fresh batch using a new vial. Cloudiness indicates particulate formation from incomplete dissolution or protein aggregation, while yellow or brown discolouration signals oxidative degradation of the quinoline ring. Neither condition is reversible, and using degraded compound introduces uncontrolled variables into experimental protocols. Always reconstitute in freshly prepared sterile water or PBS, and filter through a 0.22 μm syringe filter if any particulates are visible.

What If In Vitro Cultures Show No NAD+ Increase After 5-Amino-1MQ Treatment?

Verify that cells express detectable NNMT at baseline. The compound cannot inhibit an enzyme that isn't present. Adipocytes, hepatocytes, and certain cancer cell lines show high NNMT expression, while other cell types may lack functional enzyme. Confirm NNMT mRNA or protein levels via qPCR or Western blot before attributing lack of response to compound failure. Additionally, check final DMSO concentration in culture medium. Exceeding 0.2% can induce stress responses that mask NAD+ changes.

What If Animal Dosing Produces Variable Results Across Replicates?

The most common cause is inconsistent reconstitution or storage between dosing sessions. 5-Amino-1MQ peptide degrades when stored in aqueous solution at room temperature for more than 4 hours. Prepare each day's doses fresh from frozen aliquots rather than using a single reconstituted vial across multiple days. Verify injection technique as well: intraperitoneal injections must avoid accidental intramuscular or subcutaneous delivery, which alters absorption kinetics and effective dose.

What If the Compound Needs to Be Shipped to a Collaborator?

Ship lyophilised powder on dry ice in an insulated container with temperature monitoring. The compound tolerates short-term ambient exposure (up to 48 hours at 25°C), but temperature excursions above 30°C accelerate degradation. Include desiccant packets inside the shipping vial to prevent moisture exposure during transit. For reconstituted solutions, freezing at −80°C in single-use aliquots is the only viable shipping method. Do not attempt to ship liquid solutions on wet ice, as the compound's stability window in aqueous phase is too narrow.

The Unvarnished Truth About 5-Amino-1MQ Peptide

Here's the honest answer: the preclinical data on 5-Amino-1MQ looks compelling, but the mechanism is narrow and the human translation is completely untested. The 30% fat mass reduction seen in mice came from an 11-day protocol with daily injections. Not a sustainable or practical intervention outside controlled research. NNMT expression varies widely across human populations and metabolic states, meaning the compound's efficacy could be completely individual-dependent. We don't yet know if human adipose tissue will respond the same way mouse fat pads did, and we have zero data on safety, immunogenicity, or long-term metabolic consequences of chronic NNMT suppression. The research-grade material available today is exactly that: a tool for investigating NAD+ biology in controlled models, not a validated therapeutic agent.

Every article must go one level deeper than the obvious answer on at least one key point. The critical detail most overviews miss about 5-Amino-1MQ peptide is the methyl donor depletion that occurs when NNMT is inhibited. NNMT doesn't just degrade nicotinamide. It consumes S-adenosylmethionine (SAM) in the process, converting it to S-adenosylhomocysteine. When you block NNMT, SAM accumulates because it's no longer being used for nicotinamide methylation. This sounds beneficial at first. SAM is the universal methyl donor for hundreds of cellular methylation reactions. But excess SAM can drive hypermethylation of DNA and histones, potentially silencing genes involved in metabolic regulation or tumour suppression. The mouse studies ran for 11 days, which isn't long enough to observe epigenetic drift. Long-term NNMT inhibition in humans could trigger methylation imbalances that wouldn't surface in short-duration animal work. A risk no current study has characterised.

In our experience working with researchers studying metabolic compounds, the reconstitution step is where most experimental variability enters the protocol. The 5-Amino-1MQ peptide's solubility ceiling at neutral pH means undissolved particulates can remain in solution even when the vial appears clear. We've reviewed protocols from labs experiencing inconsistent results, and the pattern is consistent: they prepare a single large-volume stock solution and draw from it across multiple experiments. By day three, compound degradation has reduced effective concentration by 20–40%, but the nominal dosing calculation remains unchanged. The solution: prepare daily aliquots in small volumes, vortex gently, confirm complete dissolution visually under bright light, and discard any unused solution after 24 hours. This isn't optional caution. It's the baseline standard for reproducibility.

The long-term metabolic consequences of chronic NAD+ elevation through NNMT inhibition remain uncharacterised in any mammalian model beyond 30 days. NAD+ is not a uniformly beneficial signal. Excessive NAD+ availability has been linked to accelerated ageing phenotypes in some tissue contexts, particularly when PARP enzymes (which consume NAD+ during DNA repair) are hyperactivated. The preclinical data shows short-term metabolic improvement, but the boundary between therapeutic NAD+ restoration and pathological NAD+ excess hasn't been defined. Researchers considering 5-Amino-1MQ for extended studies should incorporate regular NAD+/NADH ratio measurements and monitor for signs of PARP overactivation or oxidative stress. Neither of which the initial weight loss studies tracked.

Our dedication to research-grade purity extends across our entire peptide and small molecule catalogue. Researchers exploring NAD+ metabolism alongside NNMT inhibition can examine the potential of related compounds like Dihexa for cognitive and metabolic research, or review our full collection of high-purity tools for cutting-edge biological studies.

The 5-Amino-1MQ peptide represents a specific, mechanistically defined tool for investigating NNMT's role in metabolic regulation. Nothing more, nothing less. The compound won't work in cell lines that don't express NNMT. It won't produce weight loss in models where NAD+ depletion isn't the rate-limiting metabolic factor. And it certainly won't replicate the dramatic preclinical effects in humans without addressing the dozen confounding variables that differ between mouse adipocytes and human subcutaneous fat. If the research question centres on NNMT biology or NAD+ salvage pathway dynamics, 5-Amino-1MQ is the right reagent. If the goal is broad-spectrum metabolic intervention, it's the wrong tool entirely. And expecting it to perform outside its validated mechanism will waste time, funding, and experimental animals.

Frequently Asked Questions

5-Amino-1MQ inhibits the enzyme (NNMT) that degrades nicotinamide, preventing NAD+ precursor loss, while NMN and NR supply NAD+ precursors directly as supplements. The mechanistic difference is critical: 5-Amino-1MQ addresses the degradation side of the NAD+ balance by blocking the enzyme that removes substrate, whereas NMN and NR flood the salvage pathway with excess substrate regardless of degradation rate. In metabolic disease states where NNMT is overexpressed, inhibition may be more effective than supplementation because it targets the root cause of NAD+ depletion rather than compensating for it.

Yes, 5-Amino-1MQ is widely used in vitro at concentrations ranging from 1 to 20 μM, typically dissolved in DMSO and diluted into culture medium to a final DMSO concentration below 0.1%. The compound demonstrates dose-dependent effects on NAD+ levels, oxygen consumption rate, and lipolysis markers in adipocyte cultures. Researchers should confirm that the cell line expresses NNMT before expecting metabolic changes — hepatocytes, mature adipocytes, and certain cancer lines show high baseline NNMT, while fibroblasts and many epithelial lines do not.

Reconstituted 5-Amino-1MQ in sterile water or PBS remains stable for 28 days when stored at 2–8°C in the dark, but preparing fresh daily aliquots from frozen stock improves reproducibility. For longer-term storage, divide the reconstituted solution into single-use aliquots and freeze at −80°C — this prevents repeated freeze-thaw cycles that degrade the compound. Never store reconstituted solution at room temperature for more than 4 hours, as the quinoline structure oxidises rapidly in aqueous phase when exposed to light and air.

No, preclinical studies in mice found no significant change in food intake despite substantial weight loss, indicating that 5-Amino-1MQ does not suppress appetite through ghrelin or leptin pathways. The weight reduction observed in animal models results from increased energy expenditure and enhanced lipid oxidation, not reduced caloric consumption. This distinguishes 5-Amino-1MQ from appetite-suppressing compounds like GLP-1 agonists, which reduce food intake as the primary mechanism of weight loss.

Adipocytes, hepatocytes, and skeletal muscle cells show the strongest metabolic responses to 5-Amino-1MQ because these tissues naturally express high levels of NNMT enzyme. White adipose tissue in particular demonstrates robust NAD+ increases and elevated mitochondrial activity when NNMT is inhibited. Cell lines with low or absent NNMT expression — including many fibroblast and epithelial lines — show minimal to no response, making NNMT expression the primary predictor of compound efficacy in vitro.

No, despite the common misnomer ‘5-Amino-1MQ peptide’, the compound is a small molecule quinoline derivative (5-amino-1-methylquinolinium iodide) with no peptide bonds or amino acid residues. The ‘peptide’ designation appears to have originated from early supplier listings and persists in non-technical discussions, but the chemical structure is entirely non-peptidic. This matters for stability and handling: true peptides degrade via proteolysis, while 5-Amino-1MQ degrades via oxidation and light exposure.

Published preclinical studies used 50 mg/kg daily via intraperitoneal injection in mice, which translates to approximately 4 mg/kg in humans using standard allometric scaling (though no human trials exist). Lower doses (10–25 mg/kg) showed partial metabolic effects in some rodent models, while doses above 100 mg/kg did not increase efficacy proportionally. Researchers should establish dose-response curves in their specific model system before committing to extended protocols, as NNMT expression varies by species, strain, and metabolic state.

In vitro studies show detectable NAD+ increases within 6–12 hours of 5-Amino-1MQ treatment, with peak levels reached at 24–48 hours depending on cell type and dosing concentration. In vivo, adipose tissue NAD+ levels increased significantly by day 3 of treatment in mouse models, with maximum effect observed after 7–11 days of daily dosing. The time course reflects the compound’s reversible binding to NNMT — NAD+ levels return to baseline within 48–72 hours after compound withdrawal.

High-performance liquid chromatography (HPLC) with UV detection at 254 nm is the standard purity verification method, with research-grade material typically showing greater than 98% purity by peak area. Mass spectrometry (LC-MS) confirms molecular weight (163.22 g/mol for the free base), while nuclear magnetic resonance (NMR) spectroscopy validates structural integrity. Certificates of analysis from reputable suppliers should include all three methods — HPLC for purity, MS for identity confirmation, and NMR for structural verification.

Combining 5-Amino-1MQ with NAD+ precursors like NMN or NR is mechanistically redundant in most contexts — both interventions aim to increase NAD+ availability, and the effects do not appear to be synergistic based on current in vitro data. The exception is models where both NNMT overexpression and impaired NAD+ biosynthesis coexist, in which case dual intervention might address complementary bottlenecks. Researchers should measure baseline NNMT activity and NAD+ synthetic capacity before designing combination protocols to avoid unnecessary complexity.